Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs First Solar, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.44 (market cap $39.89B), while First Solar, Inc. trades at $219.04 (market cap $24.48B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and First Solar, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FSLR | |
|---|---|---|
Market Cap | $39.89B | $24.48B |
Sector | Health | Technology |
52-Week High | $491.22 | $318.30 |
52-Week Low | $278.09 | $160.84 |
Enterprise Value | $38.15B | $22.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
First Solar (FSLR) trades at $227.83, down 0.29% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 30.73% net income margin and 18.44% ROE, supported by $2.06B in operating cash flow for 2025. Recent earnings beat expectations in Q1 2026 but missed in prior quarters, while a securities class action lawsuit filed in July 2026 adds near-term uncertainty. Valuation metrics appear reasonable with a P/E of 14.72 and P/S of 4.52.
The outlook is mixed: analyst consensus remains bullish with a $271.55 price target (61.64% buy ratings), but legal risks and technical weakness suggest caution. Upside hinges on execution against 2026 guidance of $1.7B net income, while downside risks include litigation outcomes and competitive pressures in solar manufacturing. Cash flow strength and low debt support resilience amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
